You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美生化药厂Biogen研发老人痴呆药被指有效 股价急弹逾四成
阿思达克 11-05 10:12
《路透》报道,美国食品及药物管理局表示,美国生化药厂Biogen(BIIB.US)研发针对阿兹海默症(老人痴呆症)的新抗体药Aducanumab,有非常具说服力证据展示其有效性,意味该新药获批使用机会增加。消息刺激Biogen及研发夥伴日本制药公司卫采(Eisai)股价分别急涨44%至46%。同时研发相关药物的药厂如礼来(Eli Lilly)(LLY)股价亦上涨13%。

报道指,美国食品及药物管理局最快明年3月批准该药使用,该药亦将成为首款推出可减缓阿兹海默症病情的药物。外来专家将於明日(6日)检视有关结果,并决定是否建议该药批准使用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account